Given that everolimus showed antitumor activity in preclinical models of pancreatic cancer and breast cancer metastasis33, we inferred that everolimus may be a therapeutic agent for WSB2/mTOR axis-mediated HCC progression. Here, MTOR is linked to pancreatic neoplasm.